Trump's Marijuana Rescheduling Push Is Back in Focus. Is Tilray Stock Finally a Buy?

A federal appeals court allowed the Trump administration's marijuana rescheduling process to continue, preserving a potential path for cannabis to move from Schedule I to Schedule III, though the underlying legal challenges remain unresolved. Tilray reported record fiscal 2026 revenue of $915 million, 34% growth in international medical-cannabis revenue, roughly $235 million of cash and securities, and net debt reduced to $700,000. Management expects fiscal 2027 adjusted EBITDA of $68 million-$75 million, but Schedule III would primarily expand Tilray's longer-term U.S. medical opportunity rather than immediately open the U.S. recreational market; domestic multistate operators may see more direct benefits.

Analysis

The cleanest economic exposure is not TLRY but U.S. operators burdened by IRC Section 280E. If Schedule III becomes effective and 280E no longer applies, GTBIF, CURLF, TCNNF and VRNOF could convert a large portion of currently non-deductible operating expense into cash-tax savings; the resulting FCF uplift should matter more than headline EBITDA growth and could drive rapid deleveraging or capital returns. MSOS is the more liquid basket expression, though its discount/premium and constituent concentration need monitoring.

TLRY’s reform optionality is longer-duration and less directly monetizable. Its U.S. medical opportunity requires product-registration, distribution and commercial execution steps after any federal action, while its beverage/hospitality exposure makes consolidated margins more sensitive to consumer demand and integration performance than to cannabis policy alone. The market may initially price TLRY as a high-beta reform proxy, creating a disconnect between its likely near-term earnings sensitivity and that of U.S. MSOs.

Over the next days to three months, legal briefing milestones, DEA procedural timing and any IRS clarification on 280E are the relevant catalysts; a final scheduling action without tax clarity would likely produce a sharp but potentially reversible sector rally. Over 6-18 months, the larger upside is lower cost of capital and normalized institutional ownership for operators with scaled dispensary footprints. The key falsifier is a court stay, adverse merits ruling, or administrative delay that pushes final implementation beyond 2027; separately, weaker same-store sales would limit the value of any tax windfall.

Contrarian view: legalization enthusiasm can overstate the addressable-market change because scheduling alone does not create interstate commerce or solve state-level price compression. Favor operators that can retain tax savings rather than compete them away through discounting; wholesale-heavy and oversupplied state exposure remains a structural risk.

Key Decisions for Investors

• Initiate a 3-6 month pair: long MSOS versus short TLRY in equal dollar beta-adjusted exposure. The trade captures the differential cash-tax benefit to U.S. operators while reducing binary sector-policy risk; reassess if TLRY materially outperforms MSOS following a procedural headline without an accompanying DEA/IRS milestone.
• For higher-conviction accounts, build a basket long GTBIF, CURLF and TCNNF over 1-3 months, sized modestly given OTC liquidity and federal-policy volatility. Add only after verification of each issuer’s cash-tax rate, 280E exposure and leverage maturity schedule; the thesis is invalidated by a legal stay or evidence that state-level pricing pressure absorbs the tax benefit.
• Do not chase TLRY on a rescheduling headline. Treat it as a watch item pending evidence that international medical growth and beverage/hospitality integration can support the FY2027 EBITDA range without policy upside; a guidance reduction or renewed working-capital cash burn would outweigh the policy optionality.
• Set event alerts for DEA final-rule publication, court briefing/calendar updates and explicit IRS treatment of 280E. A final Schedule III rule with clear 280E relief is the trigger to increase MSOS/MSO exposure; a rule lacking tax implementation detail is more likely a short-lived sentiment rally than an earnings re-rating.